Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Bernard

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Nature Communications|August 15, 2025
Efficient fibre-pigtailed source of indistinguishable single photonsNico Margaria, Florian Pastier, Thinhinane Bennour, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trialGuilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2018
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 TrialAlice Bernard-Tessier, Emmanuelle Jeannot, David Guenat, et al.
Current Oncology Reports|July 27, 2024
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive ReviewLaurent Mathiot, Capucine Baldini, Octave Letissier, et al.
JCO Precision Oncology|August 7, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene AlterationsMihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, et al.
BMJ Supportive & Palliative Care|August 30, 2022
PALLIA 10 score in phase I cancer studiesKaïssa Ouali, Christine Mateus, Arianne Laparra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyMark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.
BMJ Open|September 22, 2025
Randomised controlled study investigating standard dose continuous renal replacement therapy (CRRT) versus low-dose CRRT in critically ill patients with acute kidney injury (AKI): study protocol for a prospective, randomised, controlled, international, multicentre trial (the 'Ketzerei' trial)Christian Strauß, Mahan Sadjadi, Thilo von Groote, et al.
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Nature Communications|August 15, 2025
Efficient fibre-pigtailed source of indistinguishable single photonsNico Margaria, Florian Pastier, Thinhinane Bennour, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trialGuilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2018
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 TrialAlice Bernard-Tessier, Emmanuelle Jeannot, David Guenat, et al.
Current Oncology Reports|July 27, 2024
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive ReviewLaurent Mathiot, Capucine Baldini, Octave Letissier, et al.
JCO Precision Oncology|August 7, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene AlterationsMihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, et al.
BMJ Supportive & Palliative Care|August 30, 2022
PALLIA 10 score in phase I cancer studiesKaïssa Ouali, Christine Mateus, Arianne Laparra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyMark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.
BMJ Open|September 22, 2025
Randomised controlled study investigating standard dose continuous renal replacement therapy (CRRT) versus low-dose CRRT in critically ill patients with acute kidney injury (AKI): study protocol for a prospective, randomised, controlled, international, multicentre trial (the 'Ketzerei' trial)Christian Strauß, Mahan Sadjadi, Thilo von Groote, et al.
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.
Pageof 6